{
    "Question_1": {
        "Context": "The gastrin-releasing peptide receptor (GRPR) is known to be overexpressed in a majority of prostate cancer cases, making it a potential target for diagnostic and therapeutic applications in cancer treatment.",
        "Question": "What percentage range of prostate cancer cases exhibit overexpression of the GRPR?",
        "A": "10-25%",
        "B": "25-50%",
        "C": "63-100%",
        "D": "50-75%",
        "Answer": "C",
        "Source": "The gastrin-releasing peptide receptor (GRPR) represents a promising target in prostate cancer radiotheranostics. It is a member of the bombesin family of receptors and it is overexpressed in 63\u2013100% of all prostate cancer cases while having a low expression level in healthy tissues of the body, with the exception of the pancreas and the gastrointestinal tract."
    },
    "Question_2": {
        "Context": "In the development of peptide-based radiotheranostics, radiolabeled GRPR antagonists have been found to achieve higher tumor uptake and retention compared to agonists, despite lower internalization in tumor cells.",
        "Question": "Compared to GRPR agonists, how do radiolabeled GRPR antagonists perform in terms of tumor uptake and retention?",
        "A": "Lower tumor uptake and retention",
        "B": "Higher tumor uptake and retention",
        "C": "Equal tumor uptake and retention",
        "D": "Variable tumor uptake and retention depending on the tumor type",
        "Answer": "B",
        "Source": "Several studies have demonstrated that radiolabeled GRPR antagonists achieve higher tumor uptake and retention in comparison with agonists, despite their significantly inferior internalization in tumor cells."
    },
    "Question_3": {
        "Context": "Neprilysin (NEP) is a peptidase known to degrade certain peptides in the bloodstream, potentially affecting the stability of peptide-based radiopharmaceuticals.",
        "Question": "What role does neprilysin (NEP) play in the stability of peptide-based radiopharmaceuticals in the bloodstream?",
        "A": "It increases their stability",
        "B": "It has no effect on their stability",
        "C": "It decreases their stability by degrading them",
        "D": "It changes their target specificity",
        "Answer": "C",
        "Source": "However, their stability in the circulation was found to be compromised by the proteolytic action of neprilysin (NEP)."
    },
    "Question_4": {
        "Context": "Radiolabeled peptides can be designed with modifications to enhance their resistance to degrading enzymes such as neprilysin, potentially improving their tumor uptake and retention.",
        "Question": "What modification can be made to radiolabeled peptides to improve their resistance to degradation by enzymes like neprilysin?",
        "A": "Decreasing the overall charge of the peptide",
        "B": "Shortening the amino acid chain",
        "C": "Introducing structural changes to the native sequence",
        "D": "Increasing the hydrophilicity of the peptide",
        "Answer": "C",
        "Source": "Furthermore, their short amino acid chains, in combination with the structural changes introduced in the native sequence lead to enhanced resistance to degrading peptidases in the blood."
    },
    "Question_5": {
        "Context": "The use of radiometals for labeling peptides in radiotheranostics allows for diagnostic imaging and therapeutic applications, with different radiometals offering various advantages.",
        "Question": "Which of the following radiometals is commonly used for labeling peptides in therapeutic applications?",
        "A": "Ga-68",
        "B": "Lu-177",
        "C": "F-18",
        "D": "Zr-89",
        "Answer": "B",
        "Source": "Recent studies have revealed the potential of radiolabeled GRPR antagonists for therapeutic applications in human cancer. Thus, the antagonists RM2 and DOTAGA-PEG2-RM26 labeled with Lu-177 displayed favourable biodistribution profiles and managed to extend survival in murine prostate cancer models."
    },
    "Question_6": {
        "Context": "In the context of radiotheranostics, the use of chelators is crucial for labeling peptides with radiometals, and different chelators can be used to accommodate various radiometals.",
        "Question": "What is the purpose of using a chelator like DOTAGA in the design of peptide-based radiopharmaceuticals?",
        "A": "To increase the peptide's affinity for the target receptor",
        "B": "To allow for labeling with trivalent radiometals",
        "C": "To enhance the peptide's resistance to enzymatic degradation",
        "D": "To reduce the peptide's renal uptake",
        "Answer": "B",
        "Source": "Unlike the open-chain tetraamine in DB15, suitable for labeling with the SPECT radionuclide Tc-99m, DOTAGA allows for labeling with a wider panel of trivalent radiometals of medical relevance, offering better perspectives for radiotheranostic applications."
    },
    "Question_7": {
        "Context": "The introduction of specific amino acids into the structure of a peptide can influence its overall charge, which may affect its interaction with the target receptor.",
        "Question": "How can the introduction of a basic amino acid like L-Arg next to a chelator in a peptide influence its interaction with a receptor?",
        "A": "It has no effect on the interaction",
        "B": "It decreases the receptor affinity",
        "C": "It increases the receptor affinity",
        "D": "It changes the peptide's metabolic stability",
        "Answer": "C",
        "Source": "Secondly, the introduction of a basic L/D-Arg next to DOTAGA was pursued in order to compensate for the positive charge loss of the N-terminal monocationic [[99mTc]Tc(O)2(N4)]+1 metal-chelate, since a positive charge at the N-terminus of bombesin analogues has been associated with high receptor affinity."
    },
    "Question_8": {
        "Context": "The stability of radiometal-chelate complexes is an important factor in the development of radiopharmaceuticals, as it affects the integrity of the labeled compound in biological systems.",
        "Question": "What is a common method to assess the stability of a radiometal-chelate complex in radiopharmaceuticals?",
        "A": "Incubation with a molar excess of EDTA",
        "B": "Measurement of the compound's hydrophobicity",
        "C": "Determination of the compound's melting point",
        "D": "Analysis of the compound's molecular weight",
        "Answer": "A",
        "Source": "Radiometal-chelate stability was assessed by incubation of test radioligand (5 \u00b5L of the reaction mixture, 115 pmol) with a \u00d7 1000 molar excess of EDTA (115 nmol, 8.7 \u00b5L) for 1 h at room temperature."
    },
    "Question_9": {
        "Context": "In vitro assays using cancer cell lines can provide insights into the specificity of radioligands for their target receptors, which is crucial for their potential application in cancer diagnosis and therapy.",
        "Question": "What in vitro method is commonly used to determine the specificity of a radioligand for its target receptor?",
        "A": "Mass spectrometry analysis",
        "B": "Western blotting",
        "C": "Cell uptake studies with and without receptor blocking",
        "D": "Polymerase chain reaction (PCR)",
        "Answer": "C",
        "Source": "For the determination of GRPR-specificity, PC-3 cells were seeded in 35 mm tissue-culture dishes and test radioligand was added to each well (1 nM). In a subset of dishes, 1 \u00b5M of the unlabeled NOTA-PEG2-RM26 was added for blocking the GRPR."
    },
    "Question_10": {
        "Context": "The biodistribution of radiolabeled peptides in animal models is a critical aspect of preclinical studies, as it provides information on the peptides' in vivo behavior and potential for clinical application.",
        "Question": "In preclinical studies, what is the significance of assessing the biodistribution of a radiolabeled peptide in animal models?",
        "A": "To determine the peptide's flavor profile",
        "B": "To evaluate the peptide's in vivo stability and target-specific uptake",
        "C": "To measure the peptide's impact on animal behavior",
        "D": "To assess the peptide's ability to induce immunogenicity",
        "Answer": "B",
        "Source": "The new DOTAGA-bioconjugates were labeled with the broadly available trivalent radiometal In-111 and their properties were compared in vitro (GRPR affinity, specificity and uptake in prostate adenocarcinoma PC-3 cells), as well as in vivo (metabolic stability in peripheral blood of healthy mice, biodistribution in PC-3 xenograft-bearing mice) to reveal the compound of choice for further study as a Lu-177 radiotherapeutic counterpart."
    }
}